Franco GCD, Fierro DJ, Cuevas SMT, Gándara AC, Candanedo GF, Domínguez RI

Language: Spanish
References: 20
Page: 100-105
PDF size: 2558.37 Kb.

ABSTRACT

Multiple endocrine neoplasia type 1 is an autosomal dominant hereditary syndrome that leads to the development of endocrine tumors in glands such as the parathyroids, pancreas, and pituitary. Pancreatic neuroendocrine tumors, which are common in this condition, may be functional or nonfunctional and pose diagnostic and therapeutic challenges due to their multifocal and heterogeneous behavior. Management requires an individualized, multidisciplinary approach. We report the case of a 32-year-old woman with multiple endocrine neoplasia type 1 and multiple pancreatic lesions detected incidentally. Imaging studies demonstrated three hypervascular pancreatic tumors with intense somatostatin receptor uptake and variable metabolic activity. The patient underwent distal pancreatectomy and splenectomy. Histopathological analysis confirmed well-differentiated neuroendocrine tumors without lymph node involvement. This case highlights the value of multimodal imaging and multidisciplinary collaboration for the diagnosis, treatment, and follow-up of pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1.

REFERENCES

1. Sadowski SM, Triponez F. Management of pancreaticneuroendocrine tumors in patients with MEN 1.Gland Surg. 2015; 4: 63-68. doi: 10.3978/j.issn.2227-684X.2014.12.01.

2. Brandi ML, Pieterman CRC, English KA, et al. Multipleendocrine neoplasia type 1 (MEN1): recommendationsand guidelines for best practice. Lancet DiabetesEndocrinol. 2025; 13: 699-721. doi: 10.1016/S2213-8587(25)00119-6.

3. Rindi G, Mete O, Uccella S, et al. Overview of the 2022WHO Classification of Neuroendocrine Neoplasms.Endocr Pathol. 2022; 33: 115-154. doi: 10.1007/s12022-022-09708-2.

4. Rupe E, Diab M, Xoubi L, et al. Imaging updateof pancreatic neuroendocrine neoplasms. SeminRoentgenol. 2025; 60: 31-43. doi: 10.1053/j.ro.2024.12.001.

5. Rinzivillo M, Partelli S, Prosperi D, et al. Clinicalusefulness of 18F-fluorodeoxyglucose positron emissiontomography in the diagnostic algorithm of advancedentero-pancreatic neuroendocrine neoplasms.Oncologist. 2018; 23: 186-192. doi: 10.1634/theoncologist.2017-0278.

6. Magi L, Prosperi D, Lamberti G, et al. Role of [18F]FDG PET/CT in the management of G1 gastro-enteropancreaticneuroendocrine tumors. Endocrine. 2022;

7. 76: 484-490. doi: 10.1007/s12020-022-03000-3.7. Rajamohan N, Khasawneh H, Singh A, et al. PET/CTand PET/MRI in neuroendocrine neoplasms. AbdomRadiol (NY). 2022; 47: 4058-4072. doi: 10.1007/s00261-022-03516-2.

8. Deng J, Liao X, Cao H. Neuroendocrine tumors ina patient with multiple endocrine neoplasia type 1syndrome: a case report and review of the literature.Medicine (Baltimore). 2023; 102: e34350. doi:10.1097/MD.0000000000034350.

9. Mills EA, DeLucia BP, Wayne CD, et al. Functionalpancreatic neuroendocrine neoplasms: anoverview. Endocrines. 2025; 6: 38. doi: 10.3390/endocrines6030038.

10. Van Beek DJ, Nell S, Pieterman CRC, et al. Prognosticfactors and survival in MEN1 patients with gastrinomas:results from the DutchMEN study group (DMSG). J SurgOncol. 2019; 120: 966-975. doi: 10.1002/jso.25667.

11. Niederle B, Selberherr A, Bartsch DK, et al. Multipleendocrine neoplasia type 1 and the pancreas: diagnosisand treatment of functioning and non-functioningpancreatic and duodenal neuroendocrine neoplasiawithin the MEN1 syndrome - an InternationalConsensus Statement. Neuroendocrinology. 2021;111: 609-630. doi: 10.1159/000511791.

12. Paiella S, Landoni L, Tebaldi S, et al. Dual-tracer(68Ga-DOTATOC and 18F-FDG) PET/CT scan andG1-G2 nonfunctioning pancreatic neuroendocrinetumors: a single-center retrospective evaluation of 124nonmetastatic resected cases. Neuroendocrinology.2022; 112: 143-152. doi: 10.1159/000514809.

13. Machado MC. Surgical treatment of pancreaticendocrine tumors in multiple endocrine neoplasiatype 1. Clinics (Sao Paulo). 2012; 67: 145-148. doi:10.6061/clinics/2012(sup01)24.

14. Sulciner ML, Clancy TE. Surgical management ofpancreatic neuroendocrine tumors. Cancers (Basel).2023; 15: 2006. doi: 10.3390/cancers15072006.

15. Xourafas D, Tavakkoli A, Clancy TE, Ashley SW. Distalpancreatic resection for neuroendocrine tumors: islaparoscopic really better than open? J GastrointestSurg. 2015; 19: 831-840. doi: 10.1007/s11605-015-2788-1.

16. Zhang L, Ventin M, Arya S, et al. Surgical andoncologic outcomes after pancreatectomy forpancreatic neuroendocrine tumor in multipleendocrine neoplasia type 1 and von Hippel-Lindausyndrome: a large, multi-institutional cohort study. JAm Coll Surg. 2026; 242: 1602-1612. doi: 10.1097/XCS.0000000000001829.

17. Ghabra S, Ramamoorthy B, Andrews SG, SadowskiSM. Surgical management and long-term evaluation ofpancreatic neuroendocrine tumors. Surg Clin North Am.2024; 104: 891-908. doi: 10.1016/j.suc.2024.02.019.

18. Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. ESRessentials: role of PET/CT in neuroendocrine tumors.Eur Radiol. 2025; 35: 1903-1912. doi: 10.1007/s00330-024-11095-7.

19. Chen J, Yang Y, Liu Y, Kan H. Prognosis analysis ofpatients with pancreatic neuroendocrine tumors aftersurgical resection and the application of enucleation.World J Surg Oncol. 2021; 19: 11. doi: 10.1186/s12957-020-02115-z.

20. Gu DY, Fu Q, Xue BY, Kan JB, Bai JA, Tang QY.Comparison of clinical features between sporadicpancreatic neuroendocrine tumors and thoseassociated with MEN1. Zhonghua Yi XueZa Zhi. 2022; 102: 1014-1019. doi: 10.3760/cma.j.cn112137-20210822-01906.